Last Activity

Id VisitTime IPAddress Area
23723984 2018-05-27 美国
23715916 2018-05-26 美国
23692998 2018-05-26 美国
23575139 2018-05-23 美国
23573628 2018-05-23 美国
23522486 2018-05-22 美国
23504263 2018-05-21 巴基斯坦
23502242 2018-05-21 南开大学
23478286 2018-05-21 上海市
23472484 2018-05-21 日本
23448249 2018-05-20 美国
23447933 2018-05-20 亚太地区
23420087 2018-05-19 江苏省苏州市
23359538 2018-05-18 江苏省南京市
23332059 2018-05-17 中国


Dr. Xi Jiang is a Principal Investigator of Department of Pharmacology, Zhejiang University School of Medicine. Dr. Jiang graduated from Fudan University College of Medicine with a B.S. degree in Basic Medicine in 2000. Mentored by Dr. Lan Ma, Dr. Jiang pursued her Ph.D. degree in pharmacology in Fudan University from 2000 to 2005. Upon graduation, Dr. Jiang, as a postdoc scholar, joined the lab co-mentored by Dr. Janet D. Rowley, a great scientist who pioneered the concept that “Cancer is a genetic disease”, and Dr. Jianjun Chen, at the University of Chicago College of Medicine. At the beginning of 2015, Dr. Jiang was promoted to Assistant Professor-Research in Department of Cancer Biology, University of Cincinnati College of Medicine. In 2017, Dr. Jiang became an Assistant Research Professor, Step III, in Department of Systems Biology, Beckman Research Institute of City of Hope. Dr. Jiang was then recruited by the Thousand Youth Talents Plan Project and joined Zhejiang University School of Medicine as a Principal Investigator in 2018.

Dr. Jiang's research focus is the molecular mechanism of leukemia epigenetics. She aims at developing novel targeted therapy thereon. Her research has resulted in more than 20 research articles in Cell, Cancer Cell, Nat Commun, etc., as well as 3 patents. Dr. Jiang’s achievements have won her several academic awards, including the Gabrielle’s Angel Foundation Award, and awards from the American Society of Hematology (ASH), the American Society of Biochemistry and Molecular Biology (ASBMB), etc.



(1) Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki A, Plas DR, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy JC, Jin J, He C, Chen J. (2018) R-2HG exhibits anti-tumor activity by targeting FTO/MYC signaling. Cell. 11; 90-105. PMID: 29249359. IF=30.4

(2) Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore L, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M, He C, Chen J. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification. Cell Stem Cell. 22; 191-205. PMID: 29290617. IF=22.4

(3) Huang H, Weng H, Sun W, Qin X, Shi H, Zhao BS, Mesquita A, Yuan CL, Hu YC, Hüttelmaier S, Strong J, Su R, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Qu L, Guan JL, He C, Yang J, Chen J. Recognition of RNA N6-methyadenosine by IGF2BP proteins Enhances mRNA Stability. Nat Cell Biol. 20 285-295. PMID: 29476152. IF=20.1

(4) Jiang Xi#, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J. (2017) Targeted inhibition of TET1 transcription as a potent therapeutic strategy for acute myeloid leukemia. Nat Commun. 13; 2099. PMID: 29235481. IF=12.1

(5) Wang Y, Skibbe JR, Hu C, Dong L, Ferchen K, Su R, Li C, Huang H, Weng H, Huang H, Qin X, Jin J, Chen J, Jiang Xi#. (2017) ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia. Sci Rep. 12; 1853. PMID: 28500307. IF=4.3

(6) Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong GM, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C, Chen J. (2017) FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell. 31; 127-141. PMID: 28017614. IF=27.4

(7) Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, Weng H, Strong J, Wang Y, Li Y, Salat J, Li S, Elkahloun AG, Yang Y, Neilly MB, Larson RA, Le Beau MM, Herold T, Bohlander SK, Liu PP, Zhang J, Li Z, He C, Jin J, Hong S, Chen J. (2016) miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 26; 11452. PMID: 27116251. IF=12.1

(8) Jiang X#, Bugno J, Hu C, Yang Y, Herold T, Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, Ferchen K, Ulrich B, Weng H, Wang Y, Huang H, Li S, Neilly MB, Larson RA, Le Beau MM, Bohlander SK, Jin J, Li Z, Bradner JE, Hong S, Chen J. (2016) Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Cancer Res. 76; 4470-4480. PMID: 27280396. IF=9.3

(9) Li Z, Chen P, Su R, Hu C, Li Y, Elkahloun AG, Zuo Z, Gurbuxani S, Arnovitz S, Weng H, Wang Y, Li S, Huang H, Neilly MB, Wang GG, Jiang X, Liu PP, Jin J, Chen J. (2016) PBX3 and MEIS1 cooperate in hematopoietic cells to drive acute myeloid leukemias characterized by a core transcriptome of the MLL-rearranged disease. Cancer Res. 76, 619-629. PMID: 26747896. IF=9.3

(10) Huang H, Jiang X, Wang J, Li Y, Song CX, Chen P, Li S, Gurbuxani S, Arnovitz S, Wang Y, Weng H, Neilly MB, He C, Li Z, Chen J. (2016) Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia. Cancer Lett. 372, 157-165. PMID: 26791235. IF=6.4

(11) Li Z, Chen P, Su R, Li Y, Hu C, Wang Y, Arnovitz S, He M, Gurbuxani S, Zuo Z, Elkahloun AG, Li S, Weng H, Huang H, Neilly MB, Wang S, Olson EN, Larson RA, Le Beau MM, Zhang J, Jiang X, Wei M, Jin J, Liu PP, Chen J. (2015) Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 126, 2005-2015. PMID: 26361793. IF=13.2

(12) He Y, Jiang X and Chen J. (2014) The role of miR-150 in normal and malignant hematopoiesis. Oncogene. 33, 3887-93. PMCID: Pending. IF=8.5

(13) Huang H*, Jiang X*, Li Z, Li Y, Song CX, He C, Sun M, Chen P, Gurbuxani S, Wang J, Hong GM, Elkahloun AG, Arnovitz S, Wang J, Szulwach K, Lin L, Street C, Wunderlich M, Dawlaty M, Neilly MB, Jaenisch R, Yang FC, Mulloy JC, Jin P, Liu PP, Rowley JD, Xu M, He C and Chen J. (2013) TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci USA. 110, 11994-11999. PMCID: PMC3718141. IF=9.7

(14) Jiang X, Huang H, Li Z, Li Y, Wang X, Gurbuxani S, Chen P, He C, You D, Zhang S, Wang J, Arnovitz S, Elkahloun A, Price C, Hong GM, Ren H, Kunjamma RB, Neilly MB, Matthews J, Xu M, Larson RA, Le Beau MM, Slany RK, Liu PP, Lu J, Zhang J, He C and Chen J. (2012) Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 16, 524-535. PMCID: PMC3480215. IF=27.4

(15) Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD and Chen J. (2012) miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci USA. 20, 19397-19402. PMCID: PMC3511140. IF=9.7

(16) Li Z*, Huang H*, Li Y*, Jiang X*, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Dohner K, Neilly MB, Price C, Lussier YA, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Bullinger L, Valk PJ, Delwel R, Lowenberg B, Liu PP, Marcucci G, Bloomfield CD, Rowley JD and Chen J. (2012) Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 119, 2314-2324. PMCID: PMC3311258. IF=13.2

(17) Jiang X and Chen J. (2012) miR-150: targeting MLL leukemia. Oncotarget. 3, 1268-1269. PMCID: PMC3717789. IF=5.2

(18) Jiang X, Yang P and Ma L. (2009) Kinase activity-independent regulation of Cyclin pathway by GRK2 Is essential for zebrafish early development. Proc Natl Acad Sci USA. 106, 10183-10188. PMCID: PMC2700943. IF=9.7


(1) Jiang X, Chen J. TET1 transcriptional inhibitors as a therapeutic strategy for acute myeloid leukemia (AML). Serial No. 62/490,184. Submitted on 4/21/2017. Pending.

(2) Chen J, Jiang X. Anti-tumor role of miR-22 with therapeutic potential in acute myeloid leukemia. Serial No. 62/416,829. Submitted on 11/3/2016. Pending.

(3) Chen J, Jiang X, Hong S, Li Z. Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Serial No. 62/349,707. Submitted on 6/14/2016. Pending.


Abstract Achievement Award for the American Society of Hematology (ASH) Annual Meeting20122014

The Committee on Cancer Biology (CCB) postdoctoral fellowship, the University of Chicago 2013

Top 3 Abstract Award for 8th Annual Meeting of the Cancer Biology Training Consortium 2012

The Gabrielle's Angel Foundation Award 2012